Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Apr 14. doi: 10.1056/NEJMoa1811744. [Epub ahead of print]

PMID:
30990260
2.

Cardiovascular adaptations associated with exercise in patients on hemodialysis.

Graham-Brown MPM, Jardine MJ, Burton JO.

Semin Dial. 2019 Mar 24. doi: 10.1111/sdi.12789. [Epub ahead of print]

PMID:
30907030
3.

Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: A general practice-based, observational study.

Jun M, Jardine MJ, Perkovic V, Pilard Q, Billot L, Rodgers A, Rogers K, Gallagher M.

PLoS One. 2019 Mar 7;14(3):e0213192. doi: 10.1371/journal.pone.0213192. eCollection 2019.

4.

Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.

Lioufas N, Toussaint ND, Pedagogos E, Elder G, Badve SV, Pascoe E, Valks A, Hawley C; IMPROVE-CKD Writing Committee.

BMJ Open. 2019 Feb 21;9(2):e024382. doi: 10.1136/bmjopen-2018-024382.

5.

Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocol.

Smyth B, Krishnan AV, Gallagher M, Kiernan M, Snelling P, Hawley C, Fernando M, Hand S, Grimley K, Burman J, Heath A, Kang A, Perkovic V, Jardine MJ.

BMJ Open. 2019 Jan 15;9(1):e023736. doi: 10.1136/bmjopen-2018-023736.

6.

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.

Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V.

Diabetes Obes Metab. 2019 May;21(5):1237-1250. doi: 10.1111/dom.13648. Epub 2019 Mar 4.

PMID:
30697905
7.

Dietary Sodium Reduction Reduces Albuminuria: A Cluster Randomized Trial.

Jardine MJ, Li N, Ninomiya T, Feng X, Zhang J, Shi J, Zhang Y, Zhang R, Zhang J, Hao J, Perkovic V, Heerspink HL, Wu Y, Yan LL, Neal B.

J Ren Nutr. 2018 Dec 24. pii: S1051-2276(18)30247-4. doi: 10.1053/j.jrn.2018.10.009. [Epub ahead of print]

PMID:
30591358
8.

Burden of Care and Quality of Life Among Caregivers for Adults Receiving Maintenance Dialysis: A Systematic Review.

Gilbertson EL, Krishnasamy R, Foote C, Kennard AL, Jardine MJ, Gray NA.

Am J Kidney Dis. 2019 Mar;73(3):332-343. doi: 10.1053/j.ajkd.2018.09.006. Epub 2018 Nov 16.

PMID:
30454885
9.

Physical component quality of life reflects the impact of time and moderate chronic kidney disease, unlike SF-6D utility and mental component SF-36 quality of life: An AusDiab analysis.

Wong MG, Ninomiya T, Liyanage T, Sukkar L, Hirakawa Y, Wang Y, Wyld MLR, Morton RL, Chadban S, Howard K, Jardine MJ.

Nephrology (Carlton). 2019 Jun;24(6):605-614. doi: 10.1111/nep.13445. Epub 2019 Apr 24.

PMID:
30039893
10.

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function.

Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V.

Circulation. 2018 Oct 9;138(15):1537-1550. doi: 10.1161/CIRCULATIONAHA.118.035901.

11.

Design and methods of the REMOVAL-HD study: a tRial Evaluating Mid cut-Off Value membrane clearance of Albumin and Light chains in HaemoDialysis patients.

Krishnasamy R, Hawley CM, Jardine MJ, Roberts MA, Cho YJ, Wong MG, Heath A, Nelson CL, Sen S, Mount PF, Pascoe EM, Darssan D, Vergara LA, Paul-Brent PA, Toussaint ND, Johnson DW, Hutchison CA.

BMC Nephrol. 2018 Apr 17;19(1):89. doi: 10.1186/s12882-018-0883-8.

12.

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics.

Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V; CREDENCE study investigators.

Am J Nephrol. 2017 Dec 13;46(6):462-472. doi: 10.1159/000484633. [Epub ahead of print]

13.

Action plan for optimizing the design of clinical trials in chronic kidney disease.

Perkovic V, Craig JC, Chailimpamontree W, Fox CS, Garcia-Garcia G, Benghanem Gharbi M, Jardine MJ, Okpechi IG, Pannu N, Stengel B, Tuttle KR, Uhlig K, Levey AS.

Kidney Int Suppl (2011). 2017 Oct;7(2):138-144. doi: 10.1016/j.kisu.2017.07.009. Epub 2017 Sep 20. Review.

14.

Closing the gap between evidence and practice in chronic kidney disease.

Jardine MJ, Kasiske B, Adu D, Alrukhaimi M, Ashuntantang GE, Basnet S, Chailimpamontree W, Craig JC, O'Donoghue DJ, Perkovic V, Powe NR, Roberts CJ, Suzuki Y, Tanaka T, Uhlig K.

Kidney Int Suppl (2011). 2017 Oct;7(2):114-121. doi: 10.1016/j.kisu.2017.07.006. Epub 2017 Sep 20. Review.

15.

Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, Monaghan H, Zhao M, Barbour S, Reich H, Cattran D, Glassock R, Levin A, Wheeler D, Woodward M, Billot L, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu Y, Agarwal R, Wang HY, Perkovic V; TESTING Study Group.

JAMA. 2017 Aug 1;318(5):432-442. doi: 10.1001/jama.2017.9362.

16.

Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.

Baigent C, Herrington WG, Coresh J, Landray MJ, Levin A, Perkovic V, Pfeffer MA, Rossing P, Walsh M, Wanner C, Wheeler DC, Winkelmayer WC, McMurray JJV; KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology Conference Participants.

Kidney Int. 2017 Aug;92(2):297-305. doi: 10.1016/j.kint.2017.04.019.

17.

Scoring Risk Scores: Considerations Before Incorporating Clinical Risk Prediction Tools Into Your Practice.

Foote C, Woodward M, Jardine MJ.

Am J Kidney Dis. 2017 May;69(5):555-557. doi: 10.1053/j.ajkd.2017.02.005. No abstract available.

PMID:
28434521
18.

A Trial of Extending Hemodialysis Hours and Quality of Life.

Jardine MJ, Zuo L, Gray NA, de Zoysa JR, Chan CT, Gallagher MP, Monaghan H, Grieve SM, Puranik R, Lin H, Eris JM, Zhang L, Xu J, Howard K, Lo S, Cass A, Perkovic V; ACTIVE Dialysis Steering Committee; Paul.

J Am Soc Nephrol. 2017 Jun;28(6):1898-1911. doi: 10.1681/ASN.2015111225. Epub 2017 Feb 1.

19.

We Need to Talk about Depression and Dialysis: but What Questions Should We Ask, and Does Anyone Know the Answers?

Hackett ML, Jardine MJ.

Clin J Am Soc Nephrol. 2017 Feb 7;12(2):222-224. doi: 10.2215/CJN.13031216. Epub 2017 Jan 26. No abstract available.

20.

Identifying and integrating patient and caregiver perspectives for clinical practice guidelines on the screening and management of infectious microorganisms in hemodialysis units.

Miller HM, Tong A, Tunnicliffe DJ, Campbell D, Pinter J, Commons RJ, Athan E, Craig JC, Gilroy N, Green J, Henderson B, Howell M, Stuart RL, van Eps C, Wong MG, de Zoysa J, Jardine MJ.

Hemodial Int. 2017 Apr;21(2):213-223. doi: 10.1111/hdi.12457. Epub 2016 Jul 8.

PMID:
27389043

Supplemental Content

Loading ...
Support Center